Literature DB >> 19794297

Prevalence of the metabolic syndrome in moderately-severely obese subjects with and without growth hormone deficiency.

C Di Somma1, R Pivonello, G Pizza, A De Rosa, G Lombardi, A Colao, S Savastano.   

Abstract

BACKGROUND AND AIM: There is a considerable heterogeneity in metabolic phenotype among equally obese subjects. Impaired GH secretion is frequent in obese patients, with GH secretion reduced up to levels that are comparable to those found in adult patients with organic GH deficiency (GHD). Low GH status exerts detrimental effects onmetabolic abnormalities in organic GHD patients. The aim of this observational, retrospective study was to investigate the prevalence of the metabolic syndrome (MetS) in moderately-severely obese subjects who met criteria for GDH (GHD) and in those with normal GH status (GH sufficient: GHS). METHODS AND
RESULTS: One-hundred and ninety-five moderately-severely obese individuals partecipated, 149 women and 46 males [bodymass index (BMI) 43.0+/-4.4 kg/m2 aged 34.3+/-11.8 yr] . Main outcome measures were: GH peak after GHRH plus arginine test, IGF-I, MetS parameters according to National Cholesterol Education Program criteria. Fifty-five subjects (27.3%) were GHD (49 females and 6 males). The prevalence of MetS parameters was 70.9% in GHD subgroup vs 52.9% in GHS (chi2=5.281; p=0.02) and the likelihood of MetS was highest in GHD subgroup (odds ratio: 2.174; 95% confidence interval 1.113 to 4.248). At the multiple regression analysis either GH peak or IGF-I were the major determinants of waist circumference (beta=-0.380, t=-6.110 and beta=-0.326, t=-4.704, respectively; p<0.001), while age and IGFI were the major determinants of MetS (beta=0.255, t= 3.342, and beta=-0.282, t=-3.270; p=0.02, respectively).
CONCLUSIONS: Among moderately-severely obese individuals the prevalence of the MetS was higher in GHD than in GHS subjects. Thus, in obese subjects, GH status investigation might be considered in the clinical evaluation of their metabolic risk profile.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19794297     DOI: 10.1007/BF03346577

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  54 in total

Review 1.  The public health impact of obesity.

Authors:  T L Visscher; J C Seidell
Journal:  Annu Rev Public Health       Date:  2001       Impact factor: 21.981

Review 2.  Pituitary insufficiency.

Authors:  S W Lamberts; W W de Herder; A J van der Lely
Journal:  Lancet       Date:  1998-07-11       Impact factor: 79.321

3.  Growth hormone treatment reduces abdominal visceral fat in postmenopausal women with abdominal obesity: a 12-month placebo-controlled trial.

Authors:  Celina Franco; John Brandberg; Lars Lönn; Björn Andersson; Bengt-Ake Bengtsson; Gudmundur Johannsson
Journal:  J Clin Endocrinol Metab       Date:  2004-12-14       Impact factor: 5.958

Review 4.  The hypothalamic-pituitary-adrenal axis activity in obesity and the metabolic syndrome.

Authors:  Renato Pasquali; Valentina Vicennati; Mauro Cacciari; Uberto Pagotto
Journal:  Ann N Y Acad Sci       Date:  2006-11       Impact factor: 5.691

5.  Comparison of metabolic risk factors between severely and very severely obese patients.

Authors:  Anna M Wolf; Cynthia Buffington; Ulrike Beisiegel
Journal:  Obesity (Silver Spring)       Date:  2006-12       Impact factor: 5.002

6.  Circulating concentrations of insulin-like growth factor-I and development of glucose intolerance: a prospective observational study.

Authors:  Manjinder S Sandhu; Adrian H Heald; J Martin Gibson; J Kennedy Cruickshank; David B Dunger; Nicholas J Wareham
Journal:  Lancet       Date:  2002-05-18       Impact factor: 79.321

7.  The obese without cardiometabolic risk factor clustering and the normal weight with cardiometabolic risk factor clustering: prevalence and correlates of 2 phenotypes among the US population (NHANES 1999-2004).

Authors:  Rachel P Wildman; Paul Muntner; Kristi Reynolds; Aileen P McGinn; Swapnil Rajpathak; Judith Wylie-Rosett; MaryFran R Sowers
Journal:  Arch Intern Med       Date:  2008-08-11

8.  The effects of central adiposity on growth hormone (GH) response to GH-releasing hormone-arginine stimulation testing in men.

Authors:  Hideo Makimura; Takara Stanley; David Mun; Sung Min You; Steven Grinspoon
Journal:  J Clin Endocrinol Metab       Date:  2008-09-02       Impact factor: 5.958

9.  Low-dose recombinant human growth hormone as adjuvant therapy to lifestyle modifications in the management of obesity.

Authors:  Stewart G Albert; Arshag D Mooradian
Journal:  J Clin Endocrinol Metab       Date:  2004-02       Impact factor: 5.958

10.  Growth hormone deficiency by growth hormone releasing hormone-arginine testing criteria predicts increased cardiovascular risk markers in normal young overweight and obese women.

Authors:  Andrea L Utz; Ami Yamamoto; Linda Hemphill; Karen K Miller
Journal:  J Clin Endocrinol Metab       Date:  2008-04-29       Impact factor: 5.958

View more
  11 in total

1.  Growth hormone deficiency and hypopituitarism in adults after complicated mild traumatic brain injury.

Authors:  Stefania Giuliano; Serafina Talarico; Lucia Bruno; Francesco Beniamino Nicoletti; Claudio Ceccotti; Antonino Belfiore
Journal:  Endocrine       Date:  2016-11-23       Impact factor: 3.633

Review 2.  Effects of growth hormone-releasing hormone on visceral fat, metabolic, and cardiovascular indices in human studies.

Authors:  Takara L Stanley; Steven K Grinspoon
Journal:  Growth Horm IGF Res       Date:  2014-12-20       Impact factor: 2.372

3.  Effects of short-term treatment with orlistat on growth hormone/insulin-like growth factor-I axis in obese post-menopausal women.

Authors:  C Di Somma; A Rivellese; G Pizza; L Patti; A De Rosa; P Cipriano; V Nedi; A Rossi; G Lombardi; A Colao; S Savastano
Journal:  J Endocrinol Invest       Date:  2011-02       Impact factor: 4.256

4.  Prevalence of pituitary hormone dysfunction, metabolic syndrome, and impaired quality of life in retired professional football players: a prospective study.

Authors:  Daniel F Kelly; Charlene Chaloner; Diana Evans; Amy Mathews; Pejman Cohan; Christina Wang; Ronald Swerdloff; Myung-Shin Sim; Jihey Lee; Mathew J Wright; Claudia Kernan; Garni Barkhoudarian; Kevin C J Yuen; Kevin Guskiewicz
Journal:  J Neurotrauma       Date:  2014-05-08       Impact factor: 5.269

5.  The visceral adiposity index is associated with insulin sensitivity and IGF-I levels in adults with growth hormone deficiency.

Authors:  Alessandro Ciresi; Stefano Radellini; Valentina Guarnotta; Carla Giordano
Journal:  Endocrine       Date:  2016-08-13       Impact factor: 3.633

Review 6.  Endocrine changes (beyond diabetes) after bariatric surgery in adult life.

Authors:  S Savastano; C Di Somma; R Pivonello; G Tarantino; F Orio; V Nedi; A Colao
Journal:  J Endocrinol Invest       Date:  2013-02-27       Impact factor: 4.256

7.  Liver status in congenital, untreated, isolated GH deficiency.

Authors:  Rachel D C A Diniz; Renata M Souza; Roberto Salvatori; Alex Franca; Elenilde Gomes-Santos; Thiago O Ferrão; Carla R P Oliveira; João A M Santana; Francisco A Pereira; Rita A A Barbosa; Anita H O Souza; Rossana M C Pereira; Alécia A Oliveira-Santos; Allysson M P Silva; Francisco J Santana-Júnior; Eugênia H O Valença; Viviane C Campos; Manuel H Aguiar-Oliveira
Journal:  Endocr Connect       Date:  2014-08-12       Impact factor: 3.335

8.  Sensitivity of various body indices and visceral adiposity index in predicting metabolic syndrome among Chinese patients with adult growth hormone deficiency.

Authors:  L Qing; R Wei; L Chan; Z Xiaoya; X Xin
Journal:  J Endocrinol Invest       Date:  2017-02-23       Impact factor: 4.256

9.  Association between serum growth hormone levels and nonalcoholic fatty liver disease: a cross-sectional study.

Authors:  Lei Xu; Chengfu Xu; Chaohui Yu; Min Miao; Xuequn Zhang; Zhongwei Zhu; Xiaoyun Ding; Youming Li
Journal:  PLoS One       Date:  2012-08-31       Impact factor: 3.240

10.  Differences in the prevalence of metabolic syndrome in boys and girls based on various definitions.

Authors:  Nizal Sarrafzadegan; Mojgan Gharipour; Masoumeh Sadeghi; Fatemeh Nouri; Sedigheh Asgary; Sonia Zarfeshani
Journal:  ARYA Atheroscler       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.